HC Wainwright Issues Pessimistic Forecast for CORT Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – HC Wainwright reduced their Q1 2025 earnings per share estimates for Corcept Therapeutics in a research note issued on Thursday, February 27th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will post earnings of $0.16 per share for the quarter, down from their prior forecast of $0.55. HC Wainwright currently has a “Buy” rating and a $115.00 price target on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. HC Wainwright also issued estimates for Corcept Therapeutics’ Q2 2025 earnings at $0.47 EPS, Q3 2025 earnings at $0.57 EPS, FY2025 earnings at $1.93 EPS, FY2026 earnings at $3.80 EPS, FY2027 earnings at $6.26 EPS and FY2028 earnings at $7.34 EPS.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by ($0.11). The business had revenue of $181.89 million for the quarter, compared to analysts’ expectations of $200.12 million. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%.

Several other analysts have also commented on the company. Piper Sandler raised their price objective on Corcept Therapeutics from $67.00 to $78.00 and gave the company an “overweight” rating in a report on Thursday, February 27th. StockNews.com cut Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Friday. Finally, Canaccord Genuity Group increased their target price on Corcept Therapeutics from $78.00 to $130.00 and gave the company a “buy” rating in a report on Thursday, January 30th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Corcept Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $99.75.

Corcept Therapeutics Stock Performance

NASDAQ CORT opened at $59.07 on Monday. Corcept Therapeutics has a fifty-two week low of $20.84 and a fifty-two week high of $75.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70. The firm has a market capitalization of $6.23 billion, a P/E ratio of 46.88 and a beta of 0.58. The stock has a 50-day simple moving average of $59.96 and a two-hundred day simple moving average of $51.65.

Insider Activity

In other Corcept Therapeutics news, insider Sean Maduck sold 20,000 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $50.39, for a total value of $1,007,800.00. Following the completion of the transaction, the insider now owns 85,318 shares in the company, valued at $4,299,174.02. The trade was a 18.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $59.46, for a total value of $130,812.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 26,600 shares of company stock valued at $1,399,576. 20.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Corcept Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Kestra Investment Management LLC purchased a new position in Corcept Therapeutics in the fourth quarter worth approximately $27,000. Capital Performance Advisors LLP acquired a new stake in shares of Corcept Therapeutics in the 3rd quarter valued at $25,000. Canada Pension Plan Investment Board purchased a new stake in shares of Corcept Therapeutics during the 4th quarter worth $40,000. National Bank of Canada FI acquired a new position in shares of Corcept Therapeutics during the fourth quarter worth $42,000. Finally, USA Financial Formulas purchased a new position in Corcept Therapeutics in the fourth quarter valued at $54,000. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.